Glucarpidase

What is Glucarpidase?[edit | edit source]

Glucarpidase (Voraxaze) is a carboxypeptidase used to treat toxic levels of methotrexate (an anticancer drug) in the blood of patients with kidney problems.

Glutamate carboxypeptidase 1CG2

This medicine is to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance (plasma methotrexate concentrations greater than 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) due to impaired renal function.

Glucarpidase is a recombinant bacterial enzyme that hydrolyzes the carboxyl- terminal glutamate residue from folic acid and classical antifolates such as methotrexate.
Glucarpidase converts methotrexate to its inactive metabolites 4-deoxy-4-amino-N10- methylpteroic acid (DAMPA) and glutamate.
Voraxaze provides an alternate non-renal pathway for methotrexate elimination in patients with renal dysfunction during high-dose methotrexate treatment.

Limitations of Use:

Voraxaze is not recommended for use in patients who exhibit the expected clearance and expected plasma methotrexate concentration.
Reducing plasma methotrexate concentration in these patients may result in subtherapeutic exposure to methotrexate.

Voraxaze can decrease leucovorin concentration, which may decrease the effect of leucovorin rescue unless leucovorin is dosed as recommended.
Voraxaze may also reduce the concentrations other folate analogs.
DAMPA (4-deoxy-4-amino-N10- methylpteroic acid), an inactive metabolite of methotrexate formed following Voraxaze administration, interferes with the measurement of methotrexate concentration using immunoassays. This interference results in an overestimation of the methotrexate concentration.

Recommended dosage:

The recommended dosage of Voraxaze is 50 Units per kilogram (kg) as a single intravenous injection administered over 5 minutes. Flush intravenous line before and after administration.

Concomitant Use with Leucovorin Rescue

When administering Voraxaze concomitantly with leucovorin, administer leucovorin at least 2 hours before or 2 hours after the Voraxaze dose.
For the first 48 hours after the dose of Voraxaze, administer the same leucovorin dose given prior to Voraxaze. Administer leucovorin at least 2 hours before or 2 hours after the dose of Voraxaze.
Beyond 48 hours after the dose of Voraxaze, administer leucovorin based on the measured methotrexate concentration. Continue leucovorin until the methotrexate concentration has been maintained below the leucovorin treatment threshold for a minimum of 3 days.

Administration:

Reconstitute the contents of the vial with 1 mL of 0.9% Sodium Chloride Injection, USP.
Roll and tilt the vial gently to mix. Do not shake.
Inspect the vial and discard Voraxaze if the solution is not clear, colorless, and free of particulate matter.
Use reconstituted Voraxaze immediately or store under refrigeration at 36° to 46°F (2° to 8°C) for up to 4 hours if not used immediately. Voraxaze contains no preservative and is supplied as a single-dose vial. Discard any unused product.
As a single intravenous injection administered over 5 minutes.

This medicine is available in fallowing doasage form:

As Injection: 1,000 Units as a lyophilized powder in a single-dose vial for reconstitution

This medicine is available in fallowing brand namesː

The most common side effects of this medicine include:

Serious hypersensitivity reactions occurred.
DAMPA (4-deoxy-4-amino-N10- methylpteroic acid), an inactive metabolite of methotrexate formed following Voraxaze administration, interferes with the measurement of methotrexate concentration using immunoassays. This interference results in an overestimation of the methotrexate concentration. Measure methotrexate concentrations within 48 hours following Voraxaze administration using a chromatographic method; immunoassays are unreliable for samples collected within 48 hours following Voraxaze administration.

In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

Overdose related information is also available online at poisonhelp.org/help.
In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

There are no available data on Voraxaze use in pregnant women or animal reproduction studies to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.

The safety and effectiveness of Voraxaze have been established in pediatric patients.

Active ingredient:

Inactive ingredients:

Glucarpidase Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.